drugset / Trial / NCT01049815
Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease
Completed
175 enrolled
Tel-Aviv Sourasky Medical Center
Genzyme, a Sanofi Company · collabWolfson Medical Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Aims of the multi-center, randomized, treatment-controlled clinical trial are to compare the efficacy of sevelamer hydrochloride to calcium-containing phosphorus binders in reducing the rate of progression of femoral and carotid intimal media thickness (IMT) thickening as measured by B-mode ultrasound in stable maintenance hemodialysis (HD) patients.
Timeline
- Start
- 2005-02
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcium carbonate | Other / unclassified | 600 mg | — |
| Subject | Sevelamer | Other / unclassified | 800 mg | — |
| Subject | Sevelamer | Other / unclassified | 3200 mg | — |